OTC Markets Group Grants Evofem Additional Time to File Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2022
Dec. 29, 2022
/PRNewswire/ — Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that it has been granted additional time by the OTC Markets Group to file its Quarterly Report on Form 10-Q for the quarter ended
September 30, 2022
(the “10-Q”). Previously, the OTC Markets Group provided until
December 29, 2022
to file the 10-Q . The extended deadline is now
January 6, 2023
Evofem Biosciences, Inc., is developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health. The Company’s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at
is a registered trademark of Evofem Biosciences, Inc.
Phexxi is an on-demand method of birth control used to prevent pregnancy. Phexxi is not effective when used after sex. For more information about Phexxi, talk to your healthcare provider and see full Product Information at
SVP, Investor Relations
Evofem Biosciences, Inc.
View original content to download multimedia:
SOURCE Evofem Biosciences, Inc.